06
November
2018

Expert Perspectives in the Management of Chronic Lymphocytic Leukemia

Expert Perspectives in the Management of Chronic Lymphocytic Leukemia
Program Summary:

The treatment paradigm for treating chronic lymphocytic leukemia [CLL] is complex and rapidly evolving in light of the continual introduction of novel agents and regimens, enhanced patient profiling information, and the increased relevance of real world data to inform treatment decisions. With many more agents and combination regimens in clinical development, this complexity will continue to grow. This activity will provide information on the optimal utilization of current and investigational therapeutic modalities to assist clinicians in keeping abreast of mechanisms for the targeting of malignant cells and of the most effective means to utilize and integrate these treatment modalities into everyday clinical practice.


This activity has been designed to provide learners with a greater ability to; apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers, differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines, explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL and summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment.
Educational Objectives

1. Apply the latest data to risk stratify and optimize treatment plans for patients with CLL based on prognostic and predictive markers

2. Differentiate between first-line and relapsed/refractory treatment approaches for the treatment of CLL using the latest evidence-based guidelines

3. Explain the emerging clinical data and ongoing trials on novel agents and therapeutic strategies that have the potential to improve patient outcomes for patients with CLL

4. Summarize evidence-based management strategies that can be used to identify and treat acute and long-term complications associated with CLL treatment including; barriers to treatment, adherence, comorbidities, advanced age, etc.
Accreditation Information:

In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity is being presented without bias and with commercial support.

Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Rush University Medical Center designates this live activity for a maximum of one (1) continuing nursing education credit(s).

Rush University Medical Center designates this live activity for a maximum of one (1) continuing education unit(s) in Pharmacy.
Speaker List:

John M Pagel, MD, PhD (Program Chair)
Affiliate Associate Member, Division of Oncology
University of Washington School of Medicine
Swedish Cancer Institute                                  
Chief of Hematologic Malignancies Program
Seattle, Washington
 
Jonathon B. Cohen, MD, MS
Assistant Professor, Hematology & Medical Oncology
Emory University School of Medicine
Director, Summer Scholars Program
Winship Cancer Institute of Emory University 
 
Parameswaran Venugopal, MD
Professor of Medicine
The Elodia Kehm Chair of Hematology
Director, Section of Hematology
Rush University Medical Center, Chicago, IL 
 
Danielle Marie Brander, MD
Assistant Professor of Medicine
Member of the Duke Cancer Institute
 
Paul Hamlin, MD
Medical Director, David H. Koch Cancer Center Memorial Sloan Kettering Cancer Center
Associate Attending – Lymphoma Service
Associate Professor Weill Cornell Medical Center
 
Sarah Rutherford, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Weill Cornell Medicine
 
Asher A. Chanan-Khan, M.B.B.S., MD
Co-Chairman, Hematologic Malignancies Program
Mayo Clinic Cancer Center
Jacksonville, FL
This activity is supported by educational grants from AbbVie, Inc, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and TG Therapeutics

Categories: Hospital Events

Don't have an account yet? Register Now!

Sign in to your account